Ralliant Corporation $RAL Shares Acquired by Canoe Financial LP

Canoe Financial LP increased its position in shares of Ralliant Corporation (NYSE:RAL) by 6.6% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 118,622 shares of the company’s stock after buying an additional 7,319 shares during the quarter. Canoe Financial LP’s holdings in Ralliant were worth $4,933,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Danske Bank A S acquired a new stake in Ralliant during the fourth quarter worth $25,000. Allworth Financial LP lifted its stake in shares of Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after purchasing an additional 293 shares during the last quarter. V Square Quantitative Management LLC acquired a new position in shares of Ralliant in the 4th quarter valued at $26,000. Palisade Asset Management LLC purchased a new position in shares of Ralliant during the 3rd quarter worth $26,000. Finally, Rothschild Investment LLC grew its holdings in shares of Ralliant by 98.1% during the 4th quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock worth $31,000 after purchasing an additional 303 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on RAL. Royal Bank Of Canada raised their price objective on Ralliant from $47.00 to $64.00 and gave the stock a “sector perform” rating in a research report on Wednesday, May 13th. Barclays upped their target price on shares of Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Morgan Stanley lifted their price target on shares of Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research report on Tuesday, June 23rd. Finally, Zacks Research raised shares of Ralliant from a “strong sell” rating to a “hold” rating in a research note on Monday, April 13th. Seven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $69.00.

Ralliant Trading Up 0.1%

RAL opened at $72.24 on Monday. Ralliant Corporation has a 52 week low of $37.27 and a 52 week high of $75.41. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. The business has a fifty day simple moving average of $58.13 and a 200-day simple moving average of $51.25. The firm has a market cap of $8.09 billion and a P/E ratio of -6.60.

Ralliant (NYSE:RAL) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm had revenue of $534.60 million for the quarter. The company’s revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, equities analysts expect that Ralliant Corporation will post 2.64 earnings per share for the current year.

Ralliant Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were given a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend was Monday, June 8th. Ralliant’s payout ratio is currently -1.83%.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.